Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3876602 in Healthy Participants

NCT06007638 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06007638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06007638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3876602 in Healthy Participants
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
August 23, 2023
Completion date
September 20, 2025
Enrollment
74 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy